Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
3.340
+0.090 (2.77%)
At close: Jan 30, 2026, 4:00 PM EST
3.360
+0.020 (0.60%)
After-hours: Jan 30, 2026, 7:55 PM EST
Rezolute Employees
Rezolute had 75 employees as of September 30, 2025. The number of employees increased by 4 or 5.63% since the number was last reported on June 30, 2025.
Employees
75
Change
4
Growth
5.63%
Revenue / Employee
n/a
Profits / Employee
-$1,029,120
Market Cap
309.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 75 | 4 | 5.63% |
| Jun 30, 2025 | 71 | 12 | 20.34% |
| Jun 30, 2024 | 59 | 8 | 15.69% |
| Jun 30, 2023 | 51 | 9 | 21.43% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Jun 30, 2021 | 26 | 3 | 13.04% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Neurogene | 107 |
| Larimar Therapeutics | 65 |
| Atea Pharmaceuticals | 56 |
| Immuneering | 54 |
| Avalo Therapeutics | 23 |
| Immix Biopharma | 21 |
| Relmada Therapeutics | 17 |
RZLT News
- 1 day ago - SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Newsfile Corp
- 6 days ago - Alger Small Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha
- 6 days ago - INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - PRNewsWire
- 9 days ago - RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - GlobeNewsWire
- 16 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - Newsfile Corp
- 18 days ago - Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PRNewsWire
- 24 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - GlobeNewsWire
- 25 days ago - Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism - GlobeNewsWire